Central NMU signaling in body weight and energy balance regulation: evidence from NMUR2 deletion and chronic central NMU treatment in mice
Common side effectsnausea, vomiting, constipationtypically resolve within 4-8 weeks
GLP1 studies show that most people regain weight after stopping the drug, often faster than people who lost weight with lifestyle changes alone
Two areas of emerging research deserve particular attention: Non-HIV metabolic populations: Several investigators have studied tesamorelin in adults with abdominal obesity and metabolic syndrome, with consistent signals toward VAT reduction and improvements in liver fat in patients with non-alcoholic fatty liver disease
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Confirm whether consultation fees, provider review fees, or lab work are included or billed separately
